Format

Send to

Choose Destination
J Neural Transm Gen Sect. 1991;84(3):233-6.

An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics.

Author information

1
Central Institute of Mental Health, Mannheim, Federal Republic of Germany.

Abstract

Eleven schizophrenics (7 females) displaying an acute psychotic episode received the partial dopamine agonist terguride in doses up to 2 mg per day. Improvement in terms of positive symptoms reduction was observed in two cases only. In contrast, in a previous clinical trial targeted at negative schizophrenic symptoms, the majority of the patients appeared to have benefited from terguride application.

PMID:
1679338
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center